← Back to Search
Pegylated Liposomal Doxorubicin: Optimizing The Dosing Schedule In Ovarian Cancer.
Published 2005 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The need for effective, well-tolerated, and convenient therapies for patients with advanced ovarian cancer has led researchers to continually refine chemotherapeutic regimens to balance efficacy with safety and tolerability in order to maintain or improve patient quality of life. In this article, we review current strategies for the optimal dosing of pegylated liposomal doxorubicin (DOXIL; Tibotec Therapeutics, a division of Ortho Biotech Products, L.P., Bridgewater, NJ, http://www.tibotec.com; Caelyx, Schering-Plough Corporation, Kenilworth, NJ, http://www.sch-plough.com) in relapsed ovarian cancer. Pegylated liposomal doxorubicin has demonstrated efficacy in the treatment of recurrent/resistant ovarian cancer in several clinical trials utilizing a dose of 50 mg/m2 every 4 weeks. The most common adverse events associated with pegylated liposomal doxorubicin treatment in these studies-hand-foot syndrome (HFS, also known as palmar-plantar erythrodysesthesia) and stomatitis-are schedule and dose dependent, respectively, and do not typically lead to discontinuation of therapy. Several phase II and retrospective studies support the use of pegylated liposomal doxorubicin 40 mg/m2 every 4 weeks (dose intensity of 10 mg/m2 weekly) to optimize clinical efficacy and minimize the occurrence of schedule- and dose-related adverse events in patients with recurrent/relapsed ovarian cancer. Further reductions in dose intensity are necessary for use in combined chemotherapy regimens. Antitumor activity was maintained, with reduced incidences of HFS and stomatitis. Given the chronic course of ovarian cancer, the improved tolerability profile of pegylated liposomal doxorubicin 40 mg/m2 combined with a convenient once-monthly dosing schedule may translate into an improved quality of life for patients with ovarian cancer.
This paper references
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
P. Rose (1998)
Advances in the management of epithelial ovarian cancer.
S. Memarzadeh (2001)
Doxil and gemcitabine combination therapy for recurrent ovarian cancer: Results of a phase II trial
R. Holloway (2004)
Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.
A. Gordon (2000)
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
O. Lyass (2000)
Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.
W. Mcguire (2000)
The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.
S. Campos (2001)
Cancer Statistics, 2005
A. Jemal (2005)
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
W. W. ten Bokkel Huinink (1997)
Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.
R. Kim (2005)
Carboplatin (PA) and pegylated liposomal doxorubicin (CA; PACA regimen) in patients with advanced ovarian cancer in late (>6 months) relapse (AOCLR): Survival results of a GINECO phase II trial
J. Ferrero (2004)
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.
B. Lund (1994)
Phase I Study of Gemcitabine and Liposomal Doxorubicin in Relapsed Ovarian Cancer
G. D'agostino (2002)
Phase 2 study of combination therapy with liposomal doxorubicin and carboplatin in patients with relapsed, platinum sensitive ovarian cancer.
D. Vorobiof (2004)
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
M. Markman (1991)
Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
M. Cantú (2002)
Re-Treatment of Patients With Recurrent Epithelial Ovarian Cancer With Cisplatin-Based Chemotherapy
D. Gershenson (1989)
Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer.
J. Stebbing (2002)
Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.
E. Bajetta (1996)
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
M. Bookman (1998)
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
F. Muggia (1997)
Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors.
S. Campos (2003)
Update on the management of ovarian cancer.
R. Ozols (2002)
Treatment of recurrent ovarian cancer: increasing options--"recurrent" results.
R. Ozols (1997)
Pegylated Liposomal Doxorubicin (Doxil®) for Metastatic Breast Cancer: The Cancer Research Network, Inc., Experience
A. Perez (2002)
Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease.
M. Harries (2002)
Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily preteated patients with relapsed ovarian cancer
J. Sehouli (2004)
Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.
M. Gore (1990)
157 Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in recurrent epithelial ovarian cancer
A. Gordon (2003)
Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.
P. Rose (2001)
Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer.
G. Bolis (1999)
Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
A. Gabizon (2001)
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
M. Parmar (2003)
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
A. Gordon (2001)
Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments].
E. Eisenhauer (1997)
Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.
M. Markman (2004)
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
M. Markman (2000)
This paper is referenced by
RNA Nanotechnology for Next Generation Targeted Drug Delivery
Fengmei Pi (2016)
Nanomedicine: novel approaches in human and veterinary therapeutics.
J. M. Irache (2011)
Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway
Jianqin Lu (2018)
Epigenetics in cancer : basic and translational aspects.
Sue Ping Lim (2012)
The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.
N. Huynh (2010)
Procede pour traiter un cancer avance de l'ovaire avec de la doxorubicine emprisonnee dans des liposomes
R. D. Alvarez (2006)
Nanoparticle Binding to Urokinase Receptor on Cancer Cell Surface Triggers Nanoparticle Disintegration and Cargo Release
S. Li (2019)
Recent developments in lipid-based pharmaceutical nanocarriers.
T. Musacchio (2011)
Delivery of drugs and biomolecules using carbon nanotubes
S. K. Vashist (2011)
Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier‐Mediated Anticancer Agents
W. Caron (2012)
Dermatologic conditions in women receiving systemic cancer therapy☆
Michelle Ferreira (2019)
Evaluation of pyrrole-2,3-dicarboxylate derivatives: Synthesis, DFT analysis, molecular docking, virtual screening and in vitro anti-hepatic cancer study
Iqbal Azad (2019)
Controlled application and scheduled removal of nanoparticle based chemotherapeutics (CARL) will reduce dose limiting adverse events in anticancer chemotherapy.
G. Puetz (2009)
Chloroquine and nanoparticle drug delivery: A promising combination
J. Pelt (2018)
Current trends in liposome research.
T. Elbayoumi (2010)
On-Command Drug Release from Nanochains Inhibits Growth of Breast Tumors
P. Peiris (2013)
Stimuli-responsive functionalized mesoporous silica nanoparticles for drug release in response to various biological stimuli.
X. Chen (2014)
Effects of PEGylated paclitaxel nanocrystals on breast cancer and its lung metastasis.
H. Zhang (2015)
Development, characterization and cancer targeting potential of surface engineered carbon nanotubes
N. Mehra (2013)
Current strategies for the development of peptide‐based anti‐cancer therapeutics
C. Borghouts (2005)
State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines.
Charlene M. Dawidczyk (2014)
Multifunctional Pharmaceutical Nanocarriers: Promises and Problems
V. Torchilin (2012)
Liposomes as Carriers of Anticancer Drugs
Sávia C. A. Lopes (2013)
Lyotropic liquid crystalline self-assembly material behavior and nanoparticulate dispersions of a phytanyl pro-drug analogue of capecitabine-a chemotherapy agent.
Xiaojuan Gong (2011)
Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?
Hisataka Kobayashi (2013)
Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents
W. Zamboni (2005)
Physicochemical Factors That Influence the Biocompatibility of Cationic Liposomes and Their Ability to Deliver DNA to the Nuclei of Ovarian Cancer SK-OV-3 Cells
Mengwei Sun (2021)
A Dose-Escalation Study of Pegylated Liposomal Doxorubicin and Oxaliplatin in Patients with Advanced Solid Tumors
A. Kotsakis (2006)
Studies of factors influencing drug efflux rates from liposomes and their impact on antitumor efficacy
M. J. W. Johnston (2006)
A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery
Joy Wolfram (2017)
Liposomes in biology and medicine.
R. Schwendener (2007)
Liposomal doxorubicin-associated acute hypersensitivity despite appropriate preventive measures
A. Chan (2007)See more